|
Study | Year | Patient type | Treatment type | Intervention | Outcome |
|
Wen et al. [16] | 2013 | Colorectal cancer
| Oxaliplatin based chemotherapy | Ca/Mg infusion | Reduction in grade 3 acute neurotoxicity |
|
Xu et al. [17] | 2013 | Gastrointestinal cancer
| Oxaliplatin based chemotherapy | Ca/Mg infusion | Reduction in grade 1 and 2 and no effect on grade 3 neurotoxicity |
|
Grothey et al. [18] | 2013 | Colon cancer | FOLFOX | Ca/Mg infusion | No reduction in cumulative sensory neurotoxicity |
|
Gobran and Nagy [19] | 2013 | Colorectal cancer | Oxaliplatin based chemotherapy | Ca/Mg infusion | Significant reduction in chemotherapy induced neuropathy |
|
de Afonseca et al. [20] | 2013 | Colorectal and gastric cancer | Oxaliplatin based chemotherapy | Vitamin E | No reduction in chemotherapy induced neuropathy |
|
Grothey et al. [21] | 2011 | Colon cancer | Oxaliplatin, 5 FU, and leucovorin | Ca/Mg infusion | No effect in cold induced sensory neuropathy Effective neuroprotective effect of Ca/Mg therapy in oxaliplatin induced peripheral neuropathy |
|
Knijn et al. [22] | 2011 | Advanced colon cancer | Capecitabine, oxaliplatin, and bevacizumab with and without cetuximab | Ca/Mg infusion | Significant reduction in chemotherapy induced neuropathy |
|
Kottschade et al. [23] | 2011 | Not specified | Taxanes, cisplatin, oxaliplatin, and carboplatin based chemotherapy | Vitamin E | No significant reduction in chemotherapy induced neuropathy |
|
Ishibashi et al. [24] | 2010 | Metastatic colorectal cancer | FOLFOX6 | Ca/Mg infusion | No significant reduction in chemotherapy induced neuropathy |
|
Chay et al. [25] | 2010 | Colorectal cancer | FOLFOX4/ Capecitabine + oxaliplatin | Ca/Mg infusion | No significant reduction in chemotherapy induced neuropathy |
|
Gamelin et al. [26] | 2004 | Colorectal cancer | Oxaliplatin based chemotherapy | Ca/Mg infusion | Low frequency of grade 3 distal paresthesia in Ca/Mg group No case of pseudolaryngospasm in Ca/Mg group |
|